FRAMINGHAM, MA and CHICAGO, IL--(Marketwire - June 02, 2008) - The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today presented final results of a Phase II clinical study designed to evaluate the safety and efficacy of the company's lead drug, Intestinal Trefoil Factor (rhITF), at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting. The GI Company's study abstract (ID: 9514 / 2006 - ITF - 009), first published online at ASCO's website on May 15, is titled, "Prophylaxis of recurrent chemotherapy-induced oral mucositis: A Phase II multicenter, randomized, placebo-controlled trial of recombinant human Intestinal Trefoil Factor (rhITF)."
